Invivyd, Inc. (IVVD)

Market Cap	70.78M
Revenue (ttm)	25.38M
Net Income (ttm)	-169.93M
Shares Out	119.96M
EPS (ttm)	-1.43
PE Ratio	n/a
Forward PE	5.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,761,965
Open	0.5900
Previous Close	0.5852
Day's Range	0.5230 - 0.5999
52-Week Range	0.3550 - 2.7400
Beta	0.41
Analysts	Strong Buy
Price Target	7.52 (+1,174.58%)
Earnings Date	May 15, 2025

About IVVD

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and trea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Forecast

According to 3 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $7.52, which is an increase of 1,174.58% from the latest price.

Price Target

$7.52

(1,174.58% upside)

Analyst Consensus: Strong Buy